The focus of our lab is to identify the somatic genomic abnormalities that mediate cancer development or progression or influence how tumors respond to therapy. We are particularly focused on discovering abnormalities that lead to distinct clinical phenotypes and reveal mechanisms of molecular pathogenesis.
Our research intersects multiple disciplines including computational science, cancer biology, molecular biology, statistics, and bioinformatics. We employ a combined experimental-computational approach, using tools such as massively parallel sequencing and both integrative and functional genomics — along with developing new companion computational methods and pipelines. We use a “bedside to bench and back” approach to identify tumor cell–specific vulnerabilities that can be therapeutically exploited in diverse malignancies. Major ongoing interests of the laboratory include, 1) exploring the clonal, evolutionary, and therapy-induced origins of recurrent and metastatic disease, 2) engineering exceptional responses to cancer therapy through a combination of phenotype-to-genotype and functional genetic studies, and 3) developing a framework for computational oncology to enrich the clinical significance of diagnostic tumor genomics.
Our goal is to explore specific facets of tumor biology and further a model of cancer medicine in which genetic data is incorporated with computational and analytical expertise to improve patient care. As members of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, we are focused on translating the novel molecular insights from our science into routine clinical practice for the benefit of patients.